Diets

mediterranean diet decreases hepatic steatosis NAFLD/MASLD liver fat

In plain terms: Does a Mediterranean diet reduce fatty liver (lower liver fat, ALT, stiffness)?

Strong support Diets

RefutedContestedStrong support

consensus score 0.82

Yes — pooled RCTs show the Mediterranean diet significantly lowers liver fat (MRI-PDFF), ALT and liver stiffness in MASLD/NAFLD, making it a first-line dietary recommendation.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

9 support 0 contradict 0 tested null 2 mixed · 11 sources, 9 independent groups

What the evidence shows

Pooled randomised trials show the Mediterranean diet lowering liver fat, liver enzymes and liver stiffness in fatty liver disease, with the benefit largely independent of weight loss. One randomised trial improved adiponectin without shifting most inflammatory markers, so the liver-fat effect is better established than a broader anti-inflammatory one.

Cochrane has no ruling yet see how our grade compares ▾

Cochrane review 2021 · considerable uncertainty Not directly comparable

SCOPE: lifestyle interventions broadly, judged on CLINICAL outcomes rather than liver-fat measurement.

“Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis (CD013156.pub2). 'The evidence indicates considerable uncertainty about the effects of the lifestyle interventions compared with no additional intervention... on any of the clinical outcomes.'”

Not directly comparable: their review asks a different question or reports an outcome we do not grade, so it neither corroborates nor contradicts this claim.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (15)

Source	Grade	Stance	Quality	Finding
Tsamos G, Kalopitas G, Evripidou K, Vasdeki D, Koufakis T, Kanavas V, Antza C, Germanidis G, Chourdakis M 2024 · Nutrients	meta-analysis	tested-null	moderate	Meta-analysis of 7 RCTs (515 NAFLD patients) of olive oil intake; primary outcome ALT. ALT MD -1.83 IU/L (95% CI -5.85 to 2.19, p=0.37, I2=69%); liver fat percentage MD 0.40 (-3.70 to 4.49, p=0.85, I2=80%); BMI MD -0.57 kg/m2 (-1.08 to -0.06). Off-scope for the MedDiet claim: exposure is olive oil, and the pool mixes olive-oil-vs-other-oil trials, trials where olive oil was the placebo for omega-3 (Scorletti) or MF4637 (Tobin), and one whole-MedDiet trial (Properzi) with no separate MedDiet estimate.
Xiong Y, Shi X, Xiong X, Li S, Zhao H, Song H, Wang J, Zhang L, You S, Ji G, Liu B, Wu N 2024 · Food Funct	meta-analysis	supports	high	Meta-analysis of RCTs found the Mediterranean diet lowered liver fat content and liver enzymes in NAFLD versus low-fat diet.
Jamil A, Chivese T, Elshaikh U, Sendall M 2024 · BMC Public Health	meta-analysis	supports	low	Systematic review/meta-analysis found the Mediterranean diet improved MASLD markers in children and adolescents.
Reddy A, Gatta PD, Mason S, Nicoll AJ, Ryan M, Itsiopoulos C, Abbott G, Johnson NA, Sood S, Roberts SK, George ES, Tierney AC 2023 · Nutr Res	RCT	mixed	moderate	MEDINA RCT: MedDiet improved adiponectin without weight loss but did not significantly change most inflammatory markers versus low-fat diet.
Bernardino M, Tiribelli C, Rosso N 2025 · Nutrients	observational	supports	low	Review of pediatric MASLD: MedDiet + activity + nutrition education associated with improved steatosis (weaker, non-RCT pediatric evidence).
Magriplis E, Kotopoulou S, Kouvari M, Myrintzou N, Smiliotopoulos T, Tsitsou S, Papakonstandinou E, Panagopoulou MV, Panagiotakos DB, Zampelas A 2026 · Nutrition research (New York, N.Y.)	observational	supports	low	Greek cross-sectional (N=1022); +1pt MedDietScore assoc. w/ 6% lower odds of MASLD (Liver Fat Score-defined), OR 0.94 (95% CI 0.90-0.99); no steatohepatitis subgroup.
Chooi YC, Magkos F, Yaligar J, Michael N, Sadananthan SA, Kway YM, Velan SS, Lim KJ, Lai X, Wong LH, Chong YS, Loo EXL, Eriksson JG 2025 · Front Nutr	observational	supports	moderate	Secondary analysis of an RCT found MedDiet adherence improved liver fat and lipids largely independent of weight loss in women with fatty liver.
Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, Shelef I, Youngster I, Shalev A, Blüher M, Ceglarek U, Stumvoll M, Tuohy K, Diotallevi C, Vrhovsek U, Hu F, Stampfer M, Shai I 2021 · Gut	RCT	supports	high	DIRECT-PLUS RCT: green-Mediterranean diet halved NAFLD and produced the greatest intrahepatic-fat loss versus other healthy diets.
Stern UM, Wagenpfeil G, Weber SN, Alqahtani SA, Michel M, Schattenberg JM 2026 · Eur J Nutr	meta-analysis	supports	high	Meta-analysis of MASLD RCTs (2018-2024): MedDiet reduced ALT (-2.93 IU/L), liver stiffness (-0.35 kPa) and MRI-PDFF (-1.37%) vs controls; ketogenic/omega-3 did not.
Tawk D, Ghader G, Khatib Y, Attieh P, Youssef T, Othman M, Harb F, Azar S, Ghadieh HE 2025 · JGH Open	observational	supports	low	Integrative review of RCTs/meta-analyses: MedDiet highlighted as particularly effective at reducing liver fat, especially combined with physical activity.
Arita VA, Cabezas MC, Hernández Vargas JA, Trujillo-Cáceres SJ, Mendez Pernicone N, Bridge LA, Raeisi-Dehkordi H, Dietvorst CAW, Dekker R, Uriza-Pinzón JP, Tawfik M, Berk KA, Massoels J, Driessen S, Tushuizen ME, Holleboom AG, Grobbee DE, Franco OH, Beigrezaei S, GRIPonMASH Consortium 2025 · BMC medicine	meta-analysis	supports	moderate	Systematic review/meta-analysis of 37 RCTs (11 assessing Mediterranean diet) in MASLD/MASH; MD vs control significantly reduced body weight (WMD -2.38 kg), BMI, waist circumference, and ALT (WMD -3.96 IU/L, 95% CI -6.54 to -1.38); GRADE-ass
Del Bo' C, Perna S, Allehdan S, Rafique A, Saad S, AlGhareeb F, Rondanelli M, Tayyem RF, Marino M, Martini D, Riso P 2023 · Nutrients	meta-analysis	mixed	moderate	Meta-analysis of 10 RCTs showed MedDiet reduced liver stiffness and waist circumference but effects on ALT/GGT and intrahepatic fat were modest and not all significant.
Bernardino M, Tiribelli C, Rosso N 2025 · Nutrients	observational	supports	moderate	Systematic (narrative) review of 25 human studies (12 olive-oil-alone, 13 MedDiet+EVOO) in MASLD; consistently reports improved hepatic steatosis, ALT/AST, and inflammatory markers with EVOO-rich/MedDiet interventions, dose- and duration-de
Zou J, Tian F, Cui S, Hou J, Li Z, Wei Y, Cui H, Li Y, Zhou S, He Z, Ma X 2025 · BMC Gastroenterol	meta-analysis	supports	moderate	Network meta-analysis of diets in MAFLD: MedDiet among the more effective patterns for improving liver function and metabolic profile.
Uluçay Kestane V, Baş M 2024 · Nutrients	RCT	supports	low	8-week energy-restricted Mediterranean-diet variants improved liver enzymes and fatty liver index in obese insulin-resistant NAFLD patients.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.